Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Wood

Showing results (241-250 of 369) with videos related to

Pageof 37
Sort By:
The Lancet. Infectious Diseases|December 18, 2018
Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settingsJulian S Peters, Jason R Andrews, Mark Hatherill, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|September 28, 2012
Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementationJoseph N Jarvis, Nelesh Govender, Tom Chiller, et al.
BMJ Open|March 12, 2017
Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocolErick Wekesa Bunyasi, Bey-Marrie Schmidt, Leila Hussein Abdullahi, et al.
The Journal of Infectious Diseases|December 19, 2015
Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV InfectionRochelle P Walensky, Margo M Jacobsen, Linda-Gail Bekker, et al.
HIV Clinical Trials|August 26, 2010
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT studyJuan Sierra-Madero, Giovanni Di Perri, Robin Wood, et al.
Tropical Medicine & International Health : TM & IH|December 17, 2009
Mortality after failure of antiretroviral therapy in sub-Saharan AfricaOlivia Keiser, Hannock Tweya, Paula Braitstein, et al.
AIDS (London, England)|February 16, 2012
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysisJason R Andrews, Stephen D Lawn, Corina Rusu, et al.
AIDS (London, England)|March 17, 2012
Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysisJanne Estill, Cindy Aubrière, Matthias Egger, et al.
AIDS (London, England)|July 9, 2010
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South AfricaMatthew P Fox, Ian M Sanne, Francesca Conradie, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2003
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patientsRobin Wood, Keikawus Arasteh, Hans-Jürgen Stellbrink, et al.
Pageof 37

Showing results (241-250 of 369) with videos related to

Sort By:
Pageof 37
The Lancet. Infectious Diseases|December 18, 2018
Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settingsJulian S Peters, Jason R Andrews, Mark Hatherill, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|September 28, 2012
Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementationJoseph N Jarvis, Nelesh Govender, Tom Chiller, et al.
BMJ Open|March 12, 2017
Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocolErick Wekesa Bunyasi, Bey-Marrie Schmidt, Leila Hussein Abdullahi, et al.
The Journal of Infectious Diseases|December 19, 2015
Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV InfectionRochelle P Walensky, Margo M Jacobsen, Linda-Gail Bekker, et al.
HIV Clinical Trials|August 26, 2010
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT studyJuan Sierra-Madero, Giovanni Di Perri, Robin Wood, et al.
Tropical Medicine & International Health : TM & IH|December 17, 2009
Mortality after failure of antiretroviral therapy in sub-Saharan AfricaOlivia Keiser, Hannock Tweya, Paula Braitstein, et al.
AIDS (London, England)|February 16, 2012
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysisJason R Andrews, Stephen D Lawn, Corina Rusu, et al.
AIDS (London, England)|March 17, 2012
Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysisJanne Estill, Cindy Aubrière, Matthias Egger, et al.
AIDS (London, England)|July 9, 2010
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South AfricaMatthew P Fox, Ian M Sanne, Francesca Conradie, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2003
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patientsRobin Wood, Keikawus Arasteh, Hans-Jürgen Stellbrink, et al.
Pageof 37